218 related articles for article (PubMed ID: 25581902)
1. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.
Faillie JL; Filion KB; Patenaude V; Ernst P; Azoulay L
Diabetes Obes Metab; 2015 Apr; 17(4):379-85. PubMed ID: 25581902
[TBL] [Abstract][Full Text] [Related]
2. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
3. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R
BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211
[TBL] [Abstract][Full Text] [Related]
4. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
Wvan der Zanden R; de Vries F; Lalmohamed A; Driessen JH; de Boer A; Rohde G; Neef C; den Heijer C
PLoS One; 2015; 10(10):e0139367. PubMed ID: 26468883
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based drugs and the risk of congestive heart failure.
Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
[TBL] [Abstract][Full Text] [Related]
6. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
Eurich DT; Weir DL; Simpson SH; Senthilselvan A; McAlister FA
Diabet Med; 2016 May; 33(5):621-30. PubMed ID: 26206341
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
8. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
[TBL] [Abstract][Full Text] [Related]
9. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.
Chou HC; Chen WW; Hsiao FY
Drug Saf; 2014 Jul; 37(7):521-8. PubMed ID: 24859164
[TBL] [Abstract][Full Text] [Related]
10. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
Laheij RJ; Sturkenboom MC; Hassing RJ; Dieleman J; Stricker BH; Jansen JB
JAMA; 2004 Oct; 292(16):1955-60. PubMed ID: 15507580
[TBL] [Abstract][Full Text] [Related]
11. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
[TBL] [Abstract][Full Text] [Related]
12. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.
Yabe D; Kuwata H; Kaneko M; Ito C; Nishikino R; Murorani K; Kurose T; Seino Y
Diabetes Obes Metab; 2015 Apr; 17(4):430-4. PubMed ID: 25146418
[TBL] [Abstract][Full Text] [Related]
13. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
[TBL] [Abstract][Full Text] [Related]
14. The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death.
Yu OH; Yin H; Azoulay L
Can J Diabetes; 2015 Oct; 39(5):383-9. PubMed ID: 25840943
[TBL] [Abstract][Full Text] [Related]
15. The natural history of community-acquired pneumonia in COPD patients: a population database analysis.
Müllerova H; Chigbo C; Hagan GW; Woodhead MA; Miravitlles M; Davis KJ; Wedzicha JA
Respir Med; 2012 Aug; 106(8):1124-33. PubMed ID: 22621820
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.
Pradhan R; Yu OHY; Platt RW; Azoulay L
BMJ Open Diabetes Res Care; 2023 Nov; 11(6):. PubMed ID: 37949470
[TBL] [Abstract][Full Text] [Related]
17. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study.
Myles PR; Hubbard RB; McKeever TM; Pogson Z; Smith CJ; Gibson JE
Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):269-75. PubMed ID: 19235776
[TBL] [Abstract][Full Text] [Related]
18. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Neef C; van den Bergh J; Vestergaard P; de Vries F; Burden AM
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1017-25. PubMed ID: 26183226
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes.
van de Garde EM; Souverein PC; Hak E; Deneer VH; van den Bosch JM; Leufkens HG
J Hypertens; 2007 Jan; 25(1):235-9. PubMed ID: 17143196
[TBL] [Abstract][Full Text] [Related]
20. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Yang W; Cai X; Han X; Ji L
Diabetes Metab Res Rev; 2016 May; 32(4):391-404. PubMed ID: 26417956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
